Methotrexate manufacturer increasing output

In what will be welcomed news to the thousands and thousands of blood cancer sufferers across the United States, including the several thousand children suffering from Acute Lymphoblastic Leukemia, Mylan, the makers of the preservative-free version of Methotrexate has issued an announcement regarding the severe shortage:

Mylan CEO Heather Bresch issued the following statement:

"We recognize the critical importance of preservative-free Methotrexate Injection in the treatment of patients with cancer, particularly the pediatric population, and share the concerns of patients and physicians about access to this important product. While Mylan has not had any manufacturing disruption related to its preservative-free Methotrexate Injection, we are aware of, and actively addressing, shortages of this vital drug resulting from manufacturing issues that other suppliers have experienced. Mylan has already ramped up its production in order to try to meet the increased demand and is aggressively working on both the manufacturing and regulatory fronts to expedite the FDA regulatory approvals necessary to further increase capacity."

Source: Therapeutics Daily